UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000002122 |
|---|---|
| Receipt number | R000002584 |
| Scientific Title | An exploratory study of administration of colistin for multidrug-resistant Pseudomonas aeruginosa infections in patients with hematological disease. |
| Date of disclosure of the study information | 2009/06/26 |
| Last modified on | 2016/02/29 23:31:46 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
An exploratory study of administration of colistin for multidrug-resistant Pseudomonas aeruginosa infections in patients with hematological disease.
Acronym
An exploratory study of administration of colistin for multidrug-resistant Pseudomonas aeruginosa infections in patients with hematological disease.
Scientific Title
An exploratory study of administration of colistin for multidrug-resistant Pseudomonas aeruginosa infections in patients with hematological disease.
Scientific Title:Acronym
An exploratory study of administration of colistin for multidrug-resistant Pseudomonas aeruginosa infections in patients with hematological disease.
Region
| Japan |
Condition
Condition
multidrug-resistant Pseudomonas aeruginosa infections in patients with hematological disease.
Classification by specialty
| Hematology and clinical oncology |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
Evaluation of the efficacy and safety of colistin as therapy for the multidrug resistance Pseudomonas aeruginosa infection.
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Exploratory
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
A clinical response at the end of colistin therapy
Key secondary outcomes
Base
Study type
Interventional
Study design
Basic design
Single arm
Randomization
Non-randomized
Randomization unit
Blinding
Open -no one is blinded
Control
Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
1
Purpose of intervention
Treatment
Type of intervention
| Medicine |
Interventions/Control_1
Colistin is administered intravenously. The dosage is 1.25-2.5mg/kg twice a day. The treetment period is between 3 and 28 days.
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| Not applicable |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
1 Patients with hematological disease. (Patients who received hematopoietic stem cell transplantation for non-hematological disease are included)
2 Multidrug-resistant Pseudomonas aeruginosa was detected by bacteria culture within one month
3 Patients with symptons due to Multidrug-resistant Pseudomonas aeruginosa infection
4 The patients who recieved intraveous antibiotic for more than three days within one week and the symptons of infection did not improve.
Key exclusion criteria
1. Allergy for colistin
2. A woman who is pregnant or has chance to be pregnant.
Target sample size
5
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Fumihiko Nakamura |
Organization
University of Tokyo Hospital
Division name
hematology and Oncology
Zip code
Address
7-3-1, Hongo, Bunkyo-ku, Tokyo, Japan
TEL
03-3815-5411
fnakamur-tky@umin.ac.jp
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Fumihiko Nakamura |
Organization
University of Tokyo Hospital
Division name
Hematology and Oncology
Zip code
Address
7-3-1, Hongo, Bunkyo-ku, Tokyo, Japan
TEL
03-3815-5411
Homepage URL
fnakamur-tky@umin.ac.jp
Sponsor or person
Institute
University of Tokyo Hospital
Department of Hamatology and Oncology
Institute
Department
Personal name
Funding Source
Organization
None
Organization
Division
Category of Funding Organization
Self funding
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2009 | Year | 06 | Month | 26 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2009 | Year | 05 | Month | 28 | Day |
Date of IRB
Anticipated trial start date
| 2009 | Year | 06 | Month | 01 | Day |
Last follow-up date
| 2017 | Year | 03 | Month | 01 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2009 | Year | 06 | Month | 25 | Day |
Last modified on
| 2016 | Year | 02 | Month | 29 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000002584
